Harrow (HROW) shares soared 11.4% in the last trading session to close at $34.93. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the ...

Pomerantz LLP is investigating claims on behalf of investors of Harrow, Inc. (“Harrow” or the “Company”) (NASDAQ: HROW). Such investors are advised ...

Fintel reports that on July 11, 2025, Cantor Fitzgerald initiated coverage of Harrow (NasdaqGM:HROW) with a Overweight ...

Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications. NASHVILLE, Tenn., June 18, 2025--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical ...

Here are some of the largest recent moves: MARSHALL WACE, LLP added 429,674 shares (+inf%) to their portfolio in Q1 2025, for an estimated $11,429,328; VOYA INVESTMENT MANAGEMENT LLC added 372,237 ...

HROW sets ambitious price targets in a new 3-year plan while showcasing strong drug growth and leveraging a proven model for $100M potential. Read the latest HROW analysis.

Harrow is a strong swing trade in the $20s, with long-term upside as sales and new product launches drive sustained profits.

How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks ...

Harrow (HROW) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

NEW YORK, July 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Harrow, Inc. ("Harrow" or the "Company") (NASDAQ: HROW). Such investors are advised to ...